Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients

Biomarkers in Medicine

Volumn 9, Issue 5, 2015, Pages 453-460

  Butrym, Aleksandra ^a   Rybka, Justyna ^a   Baczyńska, Dagmara ^a   Tukiendorf, Andrzej ^b   Kuliczkowski, Kazimierz ^a   Mazur, Grzegorz ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Acute myeloid leukemia; Expression; miR 331; Prognosis; Survival

Indexed keywords

MICRORNA; MICRORNA 331; UNCLASSIFIED DRUG; AZACITIDINE; CYTARABINE; DAUNORUBICIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONONUCLEAR CELL; OVERALL SURVIVAL; PREDICTIVE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; UPREGULATION; DISEASE FREE SURVIVAL; GENETICS; LEUKEMIA, MYELOID, ACUTE; PATHOLOGY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AZACITIDINE; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84929582000     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.14.112     Document Type: Article

References (18)

1. Babashah S, Sadeghizadeh M, Tavirani MR, Farivar S, Soleimani M. Aberrant microRNA expression and its implications in the pathogenesis of leukemias. Cell. Oncol. (Dordr.) 35(5), 317-334 (2012).
2. Garzon R, Croce CM. MicroRNAs in normal and malignant hematopoiesis. Curr. Opin. Hematol. 15(4), 352-358 (2008).
3. Pan Y, Meng M, Zhang G, Han H, Zhou Q. Oncogenic microRNAs in the genesis of leukemia and lymphoma. Curr. Pharm. Des. 20 (33) 5260-5267 (2014).
4. Fatica A. Noncoding RNAs in acute myeloid leukemia: from key regulators to clinical players. Scientifica doi:10.6064/2012/925758 (2012) (Epub ahead of print).
5. Zhao J, Lu Q, Zhu J, Fu J, Chen YX. Prognostic value of miR-96 in patients with acute myeloid leukemia. Diagn. Pathol. 29(9), 76 (2014).
6. Guo X, Guo L, Ji J et al. miRNA-331-3p directly targets E2F1 and induces growth arrest in human gastric cancer. Biochem. Biophys. Res. Commun. 398(1), 1-6 (2010).
7. Kanaan Z, Roberts H, Eichenberger MR et al. A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. Ann. Surg. 258(3), 400-408 (2013).
8. Zanette DL, Rivadavia F, Molfetta GA et al. miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz. J. Med. Biol. Res. 40(11), 1435-1440 (2007).
9. Cheson BD, Bennett JM, Kopecky KJ et al. International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J. Clin. Oncol. 21(24), 4642-4649 (2003).
10. Cox DR. Regression models and life-tables. J. Royal. Stat. Soc. Series B 34, 187-220 (1972).
11. Congdon P. Applied Bayesian Modelling. Wiley, Chichester, UK, 118-126 (2003).
12. Marcucci G, Mrózek K, Radmacher MD, Garzon R, Bloomfield CD. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 117(4), 1121-1129 (2011).
13. Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ. miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J. Biol. Chem. 284(37), 24696-24704 (2009). • Explains the pathway of miR-331 in solid tumors.
14. Epis MR, Giles KM, Kalinowski FC, Barker A, Cohen RJ, Leedman PJ. Regulation of expression of deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the activation of eIF5A, by miR-331-3p and miR-642-5p in prostate cancer cells. J. Biol. Chem. 287(42), 35251-35259 (2012). • Explains the pathway of miR-331 in solid tumors.
15. Liu XH, Sun M, Nie FQ et al. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol. Cancer 13(1), 92 (2014). • Explains the pathway of miR-331 in solid tumors.
16. Epis MR, Giles KM, Candy PA, Webster RJ, Leedman PJ. miR-331-3p regulates expression of neuropilin-2 in glioblastoma. J. Neurooncol. 116(1), 67-75 (2014). • Explains the pathway of miR-331 in solid tumors.
17. Cammarata G, Augugliaro L, Salemi D et al. Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am. J. Hematol. 85(5), 331-339 (2010).
18. WinBUGS Development Interface (WBDev). www.mrc-bsu.cam.ac.uk/bugs/winbugs/